Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: In Vitro & In Vivo Diagnostic Substances.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Lantheus Holdings, Inc. generates cash from operations, so a burn-based runway figure does not apply.
Across 24 concluded trials, 83% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| August 15, 2027 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Trial Milestone | Phase 1/Phase 2 |
| September 30, 2029 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup]) | Trial Milestone | Phase 2/Phase 3 |
Track LNTH alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LNTH in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.